Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis

被引:146
作者
Dekkers, Olaf M. [1 ,2 ]
Lagro, Joep [1 ]
Burman, Pia [3 ]
Jorgensen, Jens Otto [4 ]
Romijn, Johannes A. [1 ]
Pereira, Alberto M. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[3] Malmo Univ Hosp, Dept Endocrinol, S-20502 Malmo, Sweden
[4] Aarhus Univ Hosp, Med Dept M, DK-8000 Aarhus C, Denmark
关键词
LONG-TERM TREATMENT; FOLLOW-UP; BROMOCRIPTINE TREATMENT; PROLACTIN LEVELS; SERUM PROLACTIN; HEART-DISEASE; CABERGOLINE; THERAPY; MANAGEMENT; DISCONTINUATION;
D O I
10.1210/jc.2009-1238
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details. Objective: The aim of the study was to assess the effect of dopamine agonist withdrawal in patients with idiopathic hyperprolactinemia and prolactinomas. Data Sources: PubMed, the Cochrane Library, the Web of Science, and EMBASE were searched electronically. No restriction was made with respect to language. Study Selection: Studies reporting the proportion of normoprolactinemic patients after withdrawal of dopamine agonist or studies in which this proportion could be calculated were eligible. Both observational studies and clinical trials were eligible. Nineteen studies were included in the meta-analysis, with a total of 743 patients. Data Extraction: Data extraction was performed by two reviewers independently. Data Synthesis: The pooled proportion of patients with persisting normoprolactinemia after dopamine agonist withdrawal was 21% in a random effects model [95% confidence interval (CI), 14-30%; I-2 81%). Stratified analysis showed higher proportions of treatment success in idiopathic hyperprolactinemia (32%; 95% CI, 5-80%), compared with both microprolactinomas (21%; 95% CI, 10-37%), and macroprolactinomas (16%; 95% CI, 6-36%). In a random effects meta-regression adjusting for cause of hyperprolactinemia, a longer treatment duration was associated with treatment success (P = 0.015), whereas the use of cabergoline showed a trend of effect (P = 0.07). Conclusions: This meta-analysis showed that hyperprolactinemia will recur after dopamine agonist withdrawal in a considerable proportion of patients. The probability of treatment success was highest when cabergoline was used for at least 2 yr. (J Clin Endocrinol Metab 95: 43-51, 2010)
引用
收藏
页码:43 / 51
页数:9
相关论文
共 52 条
[31]  
KUHN JM, 1985, PRESSE MED, V14, P525
[32]   LOW-DOSES OF DOPAMINE AGONISTS IN THE LONG-TERM TREATMENT OF MACROPROLACTINOMAS [J].
LIUZZI, A ;
DALLABONZANA, D ;
OPPIZZI, G ;
VERDE, GG ;
COZZI, R ;
CHIODINI, P ;
LUCCARELLI, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (11) :656-659
[33]   SERUM PROLACTIN AND OVARIAN-FUNCTION AFTER DISCONTINUATION OF DRUG-TREATMENT FOR HYPERPROLACTINEMIA - A STUDY WITH BROMOCRIPTINE AND METERGOLINE [J].
MATTEI, AM ;
FERRARI, C ;
RAGNI, G ;
BENCO, R ;
PICCIOTTI, MC ;
RAMPINI, P ;
CALDARA, R ;
CROSIGNANI, PG .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1984, 91 (03) :244-250
[34]  
MAXSON WS, 1984, FERTIL STERIL, V41, P218
[35]   A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas [J].
Mehmet, S ;
Powrie, JK .
CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :111-113
[36]   LONG-TERM EFFECTS OF RADIOTHERAPY AND BROMOCRIPTINE TREATMENT IN PATIENTS WITH PREVIOUS SURGERY FOR MACROPROLACTINOMAS [J].
MOBERG, E ;
TRAMPE, EA ;
WERSALL, J ;
WERNER, S .
NEUROSURGERY, 1991, 29 (02) :200-205
[37]   BROMOCRIPTINE TREATMENT OF MICROPROLACTINOMAS - EVIDENCE OF STABLE PROLACTIN DECREASE AFTER DRUG WITHDRAWAL [J].
MORIONDO, P ;
TRAVAGLINI, P ;
NISSIM, M ;
CONTI, A ;
FAGLIA, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (04) :764-772
[38]   Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients [J].
Muratori, M ;
Arosio, M ;
Gambino, G ;
Romano, C ;
Biella, O ;
Faglia, G .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1997, 20 (09) :537-546
[39]   Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal [J].
Passos, VQ ;
Souza, JJS ;
Musolino, NRC ;
Bronstein, MD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3578-3582
[40]  
RASMUSSEN C, 1990, UPSALA J MED SCI, V95, P1